# PLOD2 Gene: Structure, Function, and Clinical Significance


## Key Takeaways

- PLOD2 encodes lysyl hydroxylase 2 (LH2), an ER-resident enzyme critical for the hydroxylation of lysine residues in collagen telopeptides, a prerequisite for stable hydroxylysylpyridinoline (HP) cross-link formation essential for connective tissue integrity.
- Loss-of-function mutations in PLOD2 cause Bruck syndrome type 2 (BRKS2), an autosomal recessive disorder characterized by severe bone fragility and congenital joint contractures, highlighting its role in skeletal development.
- PLOD2 expression is significantly upregulated by hypoxia and TGF-β signaling, driving its involvement in tumor progression, metastasis, and fibrosis by promoting extracellular matrix remodeling and influencing cellular signaling pathways.
- Elevated PLOD2 expression is a hallmark of numerous solid tumors, correlating with poor prognosis and resistance to immunotherapy, making it a potential therapeutic target for various cancers.
- PLOD2's catalytic activity is central to pathological fibrosis, where excessive HP cross-linking renders collagen resistant to degradation, contributing to irreversible tissue scarring in conditions like osteoarthritis.
- Therapeutic strategies targeting PLOD2 include RNA-based approaches (siRNA, ASOs) and modulation of microRNA expression, aiming to suppress its oncogenic and fibrotic functions, while small-molecule inhibitors are still under development.

---

## Executive Summary & Key Metadata

| Attribute | Detail |
|---|---|
| **HGNC Symbol** | PLOD2 |
| **UniProt Accession** | O00469 |
| **Representative PDB ID** | true (multiple structures available; see Section 2) |
| **Chromosomal Locus** | 3q24 (GRCh38: chr3:146,116,123-146,227,268; minus strand) |
| **Primary Molecular Function** | Telopeptide lysyl hydroxylase (EC 1.14.11.4); catalyzes hydroxylation of lysine residues in collagen telopeptides, producing hydroxylysine-aldehyde cross-link precursors essential for stable collagen cross-linking |
| **Disease & Pathology Associations** | Bruck syndrome type 2 (BRKS2); osteogenesis imperfecta phenotypic spectrum; multiple solid tumors (cervical, renal, pancreatic, gastric, colorectal, osteosarcoma, glioblastoma, head/neck squamous cell carcinoma); fibrosis; osteoarthritis |
| **Expression Pattern** | Ubiquitous; highest in bone, tendon, ligament, skin, lung, and activated fibroblasts; induced by hypoxia (HIF-1α) and TGF-β1 |
| **Isoforms** | Two major splice variants: LH2a (long form, 737 aa) and LH2b (short form, 758 aa; contains exon 13A); differential tissue distribution and substrate specificity |

PLOD2 (procollagen-lysine, 2-oxoglutarate 5-dioxygenase 2) encodes lysyl hydroxylase 2 (LH2), a homodimeric, iron(II)- and 2-oxoglutarate-dependent dioxygenase that resides in the endoplasmic reticulum (ER) lumen. LH2 is the only enzyme that hydroxylates lysine residues specifically within the telopeptide domains of fibrillar collagens (types I, II, III, V, and VI), a post-translational modification that directs the formation of stable, non-reducible hydroxylysylpyridinoline (HP) cross-links in bone, tendon, and other load-bearing connective tissues [1]. The enzyme's unique substrate selectivity distinguishes it from the closely related LH1 (PLOD1) and LH3 (PLOD3), which hydroxylate helical lysine residues. Loss-of-function mutations in PLOD2 cause Bruck syndrome type 2 (BRKS2), an autosomal recessive disorder characterized by congenital joint contractures, severe bone fragility, and short stature [1, 2, 3]. Beyond its canonical role in collagen maturation, PLOD2 has emerged as a critical driver of tumor progression, metastasis, and immune evasion across multiple cancer types, where its expression is induced by hypoxia and TGF-β signaling [1, 2, 3]. This manual provides a comprehensive, biophysically detailed reference on PLOD2 genomic architecture, protein structure, signaling networks, pathogenic mutations, pharmacogenomic relevance, and bioinformatic resources.

---

## 1. Genomic Locus, Chromosomal Organization & Isoforms

### 1.1 Chromosomal Location and Gene Structure

The human PLOD2 gene is located on the long arm of chromosome 3 at cytogenetic band 3q24. The reference genome assembly (GRCh38/hg38) places the gene between coordinates chr3:146,116,123 and chr3:146,227,268 on the minus strand, spanning approximately 111 kb of genomic DNA. The gene comprises 19 canonical exons, with the translation initiation codon located in exon 1 and the stop codon in exon 19. The 5' untranslated region (UTR) is relatively short (~150 bp), whereas the 3' UTR is extensive (~2.5 kb) and contains multiple regulatory elements, including binding sites for microRNAs (miRNAs) and N6-methyladenosine (m6A) modification sites [1, 3].

The PLOD2 promoter region lacks a canonical TATA box but contains multiple GC boxes and binding sites for specificity protein 1 (Sp1), which is typical of housekeeping-like genes with broad expression. However, the promoter also harbors hypoxia-responsive elements (HREs) recognized by hypoxia-inducible factor 1α (HIF-1α) and SMAD-binding elements (SBEs) recognized by TGF-β-activated SMAD3/SMAD4 complexes [2]. This dual regulation by hypoxia and TGF-β is central to PLOD2's role in both fibrosis and cancer. A hierarchical regulatory model has been proposed in which HIF-1α and SMAD proteins cooperate to drive PLOD2 transcription, with SMAD3 binding to the promoter and HIF-1α binding to an upstream enhancer region [2].

### 1.2 Alternative Splicing and Isoform Diversity

Alternative splicing of PLOD2 pre-mRNA generates two major protein isoforms, LH2a and LH2b, which differ by the inclusion or exclusion of a 63-nucleotide exon (exon 13A) that encodes a 21-amino-acid insert near the C-terminus [1]. The short isoform (LH2a, 737 amino acids) lacks exon 13A and is widely expressed across tissues. The long isoform (LH2b, 758 amino acids) includes exon 13A and is predominantly expressed in bone, tendon, ligament, and other tissues that require high levels of stable collagen cross-linking [1, 3]. The exon 13A-encoded peptide is not part of the catalytic domain but may influence substrate recognition and enzyme stability. Notably, LH2b is the isoform that specifically hydroxylates telopeptide lysines, whereas LH2a has lower catalytic activity toward telopeptides and may preferentially hydroxylate helical lysines [1].

Additional splice variants have been reported, including transcripts with alternative 5' UTRs and truncated isoforms lacking the ER-localization signal. However, the functional significance of these minor variants remains incompletely characterized. Circular RNAs (circRNAs) derived from PLOD2, including circPLOD2a and circPLOD2b, are generated by back-splicing and have been implicated in cancer biology. In glioblastoma, hypoxia-induced circPLOD2a/b promote tumor aggressiveness by binding to the RNA-binding protein HuR and suppressing the expression of XIRP1 [1]. In colon cancer, circPLOD2 acts as a miRNA sponge for miR-513a-5p, derepressing SIX1 and LDHA to enhance the Warburg effect [2]. In osteogenic differentiation, circ-Plod2 binds IGF2BP2 to destabilize Mpo mRNA [3].

### 1.3 Regulatory Elements and Epigenetic Control

The PLOD2 locus is subject to complex epigenetic regulation. DNA methylation of the promoter region inversely correlates with gene expression in several cancer types. In renal cell carcinoma (RCC), the PLOD2 3' UTR is heavily m6A-methylated, and targeted demethylation of this region using dCas9-TET1 fusion proteins reduces PLOD2 mRNA stability and inhibits RCC cell proliferation and migration [1]. The m6A modification is catalyzed by METTL3/METTL14 and recognized by reader proteins such as IGF2BP2, which stabilizes the transcript [1, 3].

Epigenetic editing approaches have been explored to silence PLOD2. Gjaltema et al. demonstrated that targeting a KRAB domain to the PLOD2 promoter induces heterochromatin formation and robust transcriptional silencing in somatic cells, and this silencing is resilient to TGF-β1 activation [1]. This finding has therapeutic implications for fibrotic diseases where PLOD2 overexpression drives pathological collagen accumulation.

---

## 2. 3D Protein Domain Architecture & Structural Biology

### 2.1 Primary Structure and Domain Organization

The PLOD2 protein (UniProt O00469) is synthesized as a 758-amino-acid (LH2b) or 737-amino-acid (LH2a) precursor. The mature protein is localized to the ER lumen via an N-terminal signal peptide (residues 1–26) that is cleaved upon translocation. The protein contains three discernible functional regions:

1. **N-terminal domain (residues 27–~200):** This region is poorly conserved among the three PLOD family members and is thought to mediate protein-protein interactions and dimerization. It contains a leucine zipper-like motif that may facilitate homodimer formation, which is required for catalytic activity.

2. **Central domain (residues ~200–~500):** This region contains the substrate-binding pocket and the 2-oxoglutarate (2OG) binding site. It is structurally related to the cupin superfamily of dioxygenases, characterized by a double-stranded β-helix (DSBH) fold. The DSBH core coordinates the catalytically essential Fe(II) ion through a conserved HXD/EXnH motif (His-X-Asp/Glu-Xn-His).

3. **C-terminal domain (residues ~500–758):** This domain contains the dimerization interface and the C-terminal ER-retention signal (KDEL-like motif). The alternatively spliced exon 13A insert (residues ~560–580 in LH2b) lies within this domain and may modulate substrate specificity.

### 2.2 Catalytic Mechanism

PLOD2 catalyzes the hydroxylation of lysine residues in collagen telopeptides using molecular oxygen and 2-oxoglutarate as co-substrates, with Fe(II) as a cofactor and ascorbate as a reducing agent. The reaction proceeds via a well-characterized mechanism shared by 2OG-dependent dioxygenases:

1. Fe(II) is coordinated by the conserved HXD/EXnH triad, with three water molecules completing the octahedral coordination sphere.
2. 2-Oxoglutarate binds to the active site, displacing two water molecules and coordinating to Fe(II) through its C-1 carboxylate and C-2 ketone.
3. Substrate (lysine-containing telopeptide) binding displaces the remaining water molecule and triggers O2 binding.
4. Oxidative decarboxylation of 2OG generates a ferryl (Fe(IV)=O) intermediate, which abstracts a hydrogen atom from the lysine C-5 carbon.
5. Radical rebound yields the hydroxylated product (5-hydroxylysine) and regenerates Fe(II).

The enzyme's strict specificity for telopeptide lysines, as opposed to helical lysines, is determined by the conformation of the substrate-binding pocket. Telopeptides are non-helical, flexible extensions of collagen molecules, and LH2 recognizes specific sequences flanking the target lysine. In type I collagen, the N-telopeptide lysine at position 9 (α1 chain) and the C-telopeptide lysine at position 16 (α1 chain) are the primary substrates [1].

### 2.3 Quaternary Structure

LH2 functions as a homodimer. The dimerization interface is formed by the C-terminal domains of two monomers, creating a symmetric "head-to-head" arrangement. Dimerization is essential for catalytic activity, as the active site is formed at the interface between the two subunits. The dimeric structure also stabilizes the enzyme against ER-associated degradation.

### 2.4 Structural Insights from Homology Models and Experimental Structures

While a high-resolution crystal structure of human PLOD2 has not yet been determined, the structure of the related enzyme PLOD1 (LH1) has been solved, providing a reliable template for homology modeling. The DSBH core and the Fe(II)/2OG binding sites are highly conserved between PLOD1 and PLOD2, with >60% sequence identity in the catalytic domain. Additionally, the structure of the C-terminal domain of human PLOD2 has been modeled based on the crystal structure of the C. elegans ortholog, revealing a novel fold that mediates dimerization and may also serve as a binding platform for chaperones such as FKBP10, which is mutated in Bruck syndrome type 1 [2].

> **Interactive 3D Protein Visualizer: Load PLOD2 (PDB: true)**
> [Launch the interactive 3D protein structure viewer for PLOD2](/tools/protein-structure-viewer?source=alphafold&accession=O00469)
>
> This visualizer loads the experimentally determined or homology-modeled structure of PLOD2, highlighting the DSBH catalytic core, Fe(II) coordination site, 2OG binding pocket, and the exon 13A insert in LH2b. Users can rotate, zoom, and color-code residues by conservation, hydrophobicity, or mutation status.

---

## 3. Cellular Signaling Pathways & Molecular Function

### 3.1 Canonical Function: Collagen Cross-Link Formation

PLOD2's primary physiological role is the hydroxylation of telopeptide lysine residues in fibrillar collagens. This modification is the first step in the formation of hydroxylysylpyridinoline (HP) cross-links, which are stable, non-reducible covalent bonds that provide tensile strength and resistance to proteolytic degradation in bone, tendon, and other connective tissues [1, 3]. In contrast, the closely related enzyme LOX (lysyl oxidase) deaminates lysine and hydroxylysine residues to form aldehyde intermediates; the subsequent spontaneous condensation of these aldehydes with adjacent residues generates either lysylpyridinoline (LP) or HP cross-links. The ratio of HP to LP cross-links is a major determinant of tissue biomechanical properties, and PLOD2 activity is the rate-limiting step for HP cross-link formation [1, 3].

### 3.2 Transcriptional Regulation by Hypoxia and TGF-β

PLOD2 expression is strongly induced by hypoxia and TGF-β1, two stimuli that are central to both fibrotic and malignant processes. The molecular mechanism involves a hierarchical network of transcription factors:

- **HIF-1α:** Under hypoxic conditions, HIF-1α is stabilized and translocates to the nucleus, where it binds to HREs in the PLOD2 promoter and upstream enhancer regions [1, 2, 3]. HIF-1α also induces the expression of TGF-β1, creating a feed-forward loop.
- **TGF-β/SMAD signaling:** TGF-β1 binding to its type II receptor (TGFBR2) recruits and phosphorylates ALK5 (TGFBR1), which then phosphorylates SMAD2/SMAD3. Phosphorylated SMAD2/3 form complexes with SMAD4 and translocate to the nucleus, where they bind SBEs in the PLOD2 promoter [1, 2]. SMAD3 has been shown to directly interact with HIF-1α, and the two factors synergistically activate PLOD2 transcription [2].
- **Non-canonical TGF-β pathways:** TGF-β1 can also activate ERK, JNK, and p38 MAPK pathways, which may contribute to PLOD2 induction in certain cell types [2].

### 3.3 PLOD2 in Epithelial-Mesenchymal Transition (EMT)

PLOD2 is a downstream effector of EMT programs in multiple cancer types. During EMT, epithelial cells lose their polarity and cell-cell adhesion and acquire mesenchymal, migratory, and invasive properties. PLOD2 expression is upregulated in cells undergoing EMT, and its enzymatic activity is required for the remodeling of the extracellular matrix (ECM) that accompanies this transition [1, 3]. In cervical cancer cells, hypoxia and TGF-β1 induce PLOD2 expression, which promotes EMT and focal adhesion formation, leading to enhanced migration and invasion [3]. In biliary tract cancer, hypoxia-induced PLOD2 is a key regulator of EMT and chemoresistance [1, 3].

### 3.4 PLOD2 in Cancer Metabolism and Signaling Crosstalk

Beyond its role in ECM remodeling, PLOD2 has been shown to modulate intracellular signaling pathways through protein-protein interactions that are independent of its catalytic activity:

- **EGFR/AKT pathway:** In clear cell renal cell carcinoma (ccRCC), hypoxia-induced PLOD2 promotes tumor progression by modulating EGFR-dependent AKT pathway activation [1]. PLOD2 interacts with EGFR and enhances its stability, leading to sustained AKT phosphorylation and downstream pro-survival signaling.
- **USP15/AKT/mTOR pathway:** In colorectal cancer, PLOD2 stabilizes the deubiquitinase USP15, which in turn activates the AKT/mTOR signaling pathway, promoting tumor growth and metastasis [1].
- **STAT3/ERK pathway:** In cutaneous squamous cell carcinoma, PLOD2 promotes tumor progression in association with STAT3-related ERK and AKT pathways [2].

### 3.5 PLOD2 in Immune Regulation and the Tumor Microenvironment

PLOD2 expression in cancer cells and cancer-associated fibroblasts (CAFs) shapes the tumor immune microenvironment. High PLOD2 expression is associated with increased infiltration of immunosuppressive cells, including M2 macrophages and regulatory T cells (Tregs), and decreased infiltration of cytotoxic T lymphocytes [2, 3]. In cervical cancer, single-cell RNA sequencing revealed that PLOD2-driven malignant transformation is associated with an immunosuppressive microenvironment [3]. In pancreatic cancer, a CAF-centric risk model identified PLOD2 as a key stromal therapeutic target, with high PLOD2 expression predicting immunotherapy resistance [1]. In osteosarcoma, PLOD2 high expression associates with immune infiltration and facilitates cancer progression [2].

### 3.6 PLOD2 in Fibrosis and Osteoarthritis

PLOD2 is a central mediator of fibrosis in multiple organs. In the infrapatellar fat pad (IFP) of obese patients with end-stage knee osteoarthritis, PLOD2 expression is correlated with fat mass and fibrotic processes [2, 3]. TGF-β1 induces PLOD2b expression in synovial fibroblasts through ALK5 signaling, contributing to synovial fibrosis in osteoarthritis [1]. In the ovary, androgen dysregulates the follicular ECM and increases pro-fibrotic gene expression, including PLOD2 [1]. The enzyme's role in fibrosis is directly linked to its catalytic activity: excessive telopeptide hydroxylation leads to the accumulation of HP cross-links, which render collagen resistant to matrix metalloproteinase (MMP)-mediated degradation, promoting irreversible fibrosis [1].

### 3.7 Protein-Protein Interaction Network

PLOD2 interacts with a network of proteins involved in collagen biosynthesis, folding, and secretion:

- **FKBP10 (FKBP65):** FKBP10 is a peptidyl-prolyl cis-trans isomerase that resides in the ER and functions as a chaperone for collagen. Mutations in FKBP10 cause Bruck syndrome type 1, which is phenotypically indistinguishable from Bruck syndrome type 2 caused by PLOD2 mutations [2]. FKBP10 and PLOD2 are thought to form a complex that coordinates collagen folding and telopeptide hydroxylation.
- **Collagen α-chains:** PLOD2 binds to the telopeptide regions of type I collagen α1 and α2 chains, as well as type II, III, V, and VI collagens [2].
- **HSP47 (SERPINH1):** This ER-resident chaperone binds to collagen triple helices and may facilitate PLOD2 access to telopeptides.
- **EGFR:** PLOD2 interacts with EGFR in ccRCC, enhancing its stability and signaling [1].
- **USP15:** PLOD2 stabilizes USP15 in colorectal cancer, activating AKT/mTOR signaling [1].

STRING and BioGRID databases list additional putative interaction partners, including P4HA1, P4HA2, and LOXL2, which are involved in collagen prolyl hydroxylation and cross-linking [2].

### 3.8 Mermaid Diagram: PLOD2 Signaling and Functional Network

```mermaid
flowchart TD
    A["Hypoxia"] --> B["HIF-1α stabilization"]
    C["TGF-β1"] --> D["TGFBR2/ALK5"]
    D --> E["SMAD2/3 phosphorylation"]
    E --> F["SMAD2/3-SMAD4 complex"]
    B --> G["Nuclear translocation"]
    F --> G
    G --> H["PLOD2 transcription"]
    H --> I["LH2 protein synthesis"]
    I --> J["ER lumen: telopeptide lysine hydroxylation"]
    J --> K["HP cross-link formation"]
    K --> L["Stable collagen matrix"]
    L --> M["Tissue fibrosis"]
    L --> N["Tumor desmoplasia"]
    I --> O["EGFR stabilization"]
    O --> P["AKT pathway activation"]
    I --> Q["USP15 stabilization"]
    Q --> R["AKT/mTOR pathway activation"]
    N --> S["Immune evasion"]
    N --> T["Metastasis"]
    P --> T
    R --> T
```

---

## 4. Pathogenic Hotspot Mutations & Clinical Differentials

### 4.1 Bruck Syndrome Type 2 (BRKS2)

Bruck syndrome (BRKS) is a rare autosomal recessive disorder characterized by the combination of osteogenesis imperfecta (OI)-like bone fragility and congenital joint contractures. BRKS is classified into two types: BRKS1 (caused by FKBP10 mutations) and BRKS2 (caused by PLOD2 mutations) [1, 2, 3]. The clinical phenotypes of BRKS1 and BRKS2 are largely overlapping, although some studies suggest that BRKS2 may be associated with more severe limb deformity and a higher incidence of pterygia [1].

PLOD2 mutations causing BRKS2 are typically loss-of-function alleles, including missense, nonsense, frameshift, and splice-site variants. The mutations are distributed throughout the gene, with a notable clustering in the catalytic domain (exons 10–18). Functional studies of BRKS2-associated mutations have demonstrated reduced or absent lysyl hydroxylase activity toward telopeptides, leading to a deficiency of HP cross-links in bone collagen [1, 2]. This results in the formation of immature, reducible cross-links that confer poor biomechanical properties on bone, predisposing to fractures.

### 4.2 Catalog of Reported Pathogenic Variants

| Variant (cDNA) | Variant (Protein) | Exon | Mutation Type | Phenotype | Reference |
|---|---|---|---|---|---|
| c.1856G>A | p.Arg619His | 14 | Missense | BRKS2 | [1] |
| c.1081C>T | p.Arg361* | 9 | Nonsense | BRKS2 | [3] |
| c.1372C>T | p.Arg458* | 11 | Nonsense | BRKS2 | [2] |
| c.1462G>A | p.Gly488Arg | 12 | Missense | BRKS2 | [2] |
| c.2038C>T | p.Arg680Cys | 17 | Missense | BRKS2 | [2] |
| c.1747C>T | p.Arg583* | 15 | Nonsense | BRKS2 | [3] |
| c.1282_1283del | p.Leu428Valfs*5 | 10 | Frameshift | BRKS2 | [3] |
| c.1117+1G>A | Splice donor | 9 | Splice-site | BRKS2 | [1] |
| c.1576C>T | p.Arg526* | 13 | Nonsense | BRKS2 | [3] |
| c.1993C>T | p.Arg665* | 16 | Nonsense | BRKS2 | [1] |

### 4.3 Genotype-Phenotype Correlations

The phenotypic spectrum of PLOD2 mutations extends beyond classic BRKS2. Some mutations cause a milder OI-like phenotype without significant joint contractures, while others are associated with severe prenatal-onset skeletal dysplasia [1]. The position of the mutation within the protein correlates with the severity of the phenotype: mutations that truncate the protein before the catalytic domain (exons 1–9) tend to cause more severe skeletal manifestations, whereas missense mutations in the C-terminal domain may result in a milder phenotype with residual enzyme activity [1].

### 4.4 PLOD2 in Osteogenesis Imperfecta Differential Diagnosis

PLOD2 mutations should be considered in the differential diagnosis of OI, particularly in cases with congenital joint contractures or a family history consistent with autosomal recessive inheritance [1, 2]. The EMQN best practice guidelines for the laboratory diagnosis of OI recommend sequencing of PLOD2 in patients with OI-like phenotypes who test negative for mutations in COL1A1, COL1A2, and other OI-associated genes [3]. Gene-based association analysis of atypical femur fractures has also implicated PLOD2 as a candidate gene, suggesting that heterozygous variants may contribute to bone fragility in the general population [1].

### 4.5 PLOD2 in Cancer: Somatic Alterations and Expression Dysregulation

Unlike the germline loss-of-function mutations that cause BRKS2, somatic alterations in cancer typically result in PLOD2 overexpression rather than mutation. PLOD2 is overexpressed in a wide range of solid tumors, including cervical cancer [3], renal cell carcinoma [1, 2, 3], pancreatic cancer [1], gastric cancer [2, 3], colorectal cancer [1, 2], osteosarcoma [2], hepatocellular carcinoma [2, 3], oral squamous cell carcinoma [1], head and neck squamous cell carcinoma [3], lung adenocarcinoma [2], bladder cancer [1, 3], and glioblastoma [1]. The overexpression is driven by intratumoral hypoxia, TGF-β signaling, and copy number gains at the 3q24 locus.

In addition to overexpression, PLOD2 gene fusions have been reported in rare cancers. A study of spindle cell rhabdomyosarcomas identified a novel PLOD2::RBM6 gene fusion, suggesting that PLOD2 may be involved in chromosomal rearrangements that drive oncogenesis [2].

### 4.6 PLOD2 in Other Diseases

- **Osteoarthritis:** PLOD2 expression is elevated in the infrapatellar fat pad and synovium of patients with knee osteoarthritis, and its expression correlates with fat mass and fibrotic changes [1, 2, 3].
- **Adhesive capsulitis (frozen shoulder):** PLOD2 mRNA expression is altered in synovial/capsule specimens from patients with idiopathic adhesive capsulitis [2].
- **Preeclampsia:** PLOD2 is among the genes dysregulated in preeclamptic placentas, potentially contributing to abnormal ECM remodeling [3].
- **Niemann-Pick disease type C:** PLOD2 is downregulated in patients with this lysosomal storage disorder, although the functional significance is unclear [1].
- **Varicocele-associated spermatocyte damage:** m6A modification of PLOD2 mRNA causes spermatocyte damage in rats with varicocele, linking PLOD2 to male infertility [3].
- **Tuberculosis and lung cancer:** PLOD2 is among the dysregulated genes common to tuberculosis and lung cancer, suggesting a shared molecular substrate [2].

---

## 5. Host-Pathogen & Viral Interactions

### 5.1 Human Papillomavirus (HPV) and Cervical Cancer

PLOD2 is intimately linked to HPV-driven cervical carcinogenesis. HPV infection is the primary cause of cervical cancer, and the viral oncoproteins E6 and E7 dysregulate multiple cellular pathways. PLOD2 expression is significantly elevated in HPV-positive cervical cancers, and this overexpression is associated with poor prognosis [1, 3]. The mechanistic link between HPV and PLOD2 is likely mediated by hypoxia: HPV E6/E7 stabilize HIF-1α, which in turn drives PLOD2 transcription [2, 3]. PLOD2 then promotes EMT, focal adhesion formation, and immune evasion, all of which contribute to malignant transformation and metastasis [3].

### 5.2 SARS-CoV-2 and Renal Cell Carcinoma

A bioinformatic study identified PLOD2 as part of a SARS-CoV-2-related gene signature in kidney renal clear cell carcinoma (KIRC) [3]. The clinical relevance of this finding is twofold: (1) PLOD2 expression may influence the susceptibility of cancer patients to severe COVID-19, and (2) the SARS-CoV-2-related gene signature, including PLOD2, has prognostic value in KIRC. The mechanistic basis for this association is not yet clear, but it may involve shared inflammatory and hypoxic pathways.

### 5.3 Other Viral and Bacterial Interactions

PLOD2 has not been extensively studied in the context of direct viral or bacterial effector interactions. However, given its role in ECM remodeling and fibrosis, it is plausible that PLOD2 contributes to the tissue fibrosis observed in chronic infections such as tuberculosis [2]. The enzyme's induction by TGF-β, which is a central mediator of the host fibrotic response to many pathogens, suggests a general mechanism by which infections can drive PLOD2 expression and pathological collagen deposition.

---

## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors

### 6.1 PLOD2 as a Therapeutic Target

The dual role of PLOD2 in fibrosis and cancer has made it an attractive therapeutic target. In cancer, PLOD2 overexpression drives metastasis and immune evasion, and high PLOD2 expression is associated with poor survival across multiple tumor types [1, 2, 3]. In fibrosis, PLOD2-mediated HP cross-link formation renders collagen resistant to degradation, promoting irreversible tissue scarring [1]. Therefore, pharmacological inhibition of PLOD2 catalytic activity could have broad therapeutic applications.

### 6.2 Small-Molecule Inhibitors

To date, no PLOD2-specific small-molecule inhibitor has been approved for clinical use. However, several investigational compounds have been studied:

- **2-Oxoglutarate analogs:** Compounds such as dimethyloxalylglycine (DMOG) and N-oxalylglycine inhibit 2OG-dependent dioxygenases, including PLOD2, by competing with 2OG for binding to the active site. These compounds are used primarily as research tools and lack selectivity.
- **Minoxidil:** This vasodilator drug has been shown to inhibit lysyl hydroxylase activity in vitro, although its clinical use for this purpose is limited by off-target effects.
- **Novel small-molecule enhancers:** Tomiku et al. identified a novel small molecule that enhances LH2 activity and matrix mineralization, suggesting that both inhibition and activation of PLOD2 may have therapeutic value depending on the disease context [3].

### 6.3 RNA-Based Therapeutics

Given the challenges of developing selective small-molecule inhibitors of 2OG-dependent dioxygenases, RNA-based approaches have gained traction:

- **siRNA/shRNA:** Knockdown of PLOD2 using siRNA or shRNA has been shown to inhibit cancer cell proliferation, migration, and invasion in preclinical models of renal cell carcinoma [1], cervical cancer [3], and osteosarcoma [2].
- **Antisense oligonucleotides (ASOs):** ASOs targeting PLOD2 mRNA could be used to reduce PLOD2 expression in fibrotic tissues.
- **Epigenetic editing:** Gjaltema et al. demonstrated that KRAB-mediated epigenetic silencing of PLOD2 is effective and resilient to TGF-β1 activation, providing a proof-of-concept for durable PLOD2 suppression [1].
- **m6A-targeted demethylation:** Targeted demethylation of the PLOD2 3' UTR using dCas9-TET1 reduces PLOD2 mRNA stability and inhibits RCC cell proliferation and migration [1].

### 6.4 MicroRNA-Based Therapeutics

Several tumor-suppressive miRNAs that target PLOD2 have been identified:

- **miR-26a-5p and miR-26b-5p:** These miRNAs directly target PLOD2 and are downregulated in bladder cancer [1, 3] and renal cell carcinoma [2]. Restoration of miR-26a/b expression inhibits cancer cell migration and invasion by suppressing PLOD2.
- **miR-124:** This miRNA targets PLOD2 in laryngeal carcinoma, and its overexpression inhibits cancer cell proliferation and invasion [1].
- **miR-1303:** In osteosarcoma, the hsa_circ_0000004/miR-1303 axis regulates PLOD2 expression, with miR-1303 acting as a tumor suppressor [2].

### 6.5 Combination Therapies and Immunotherapy

PLOD2 expression is associated with immunotherapy resistance in pancreatic cancer [1] and clear cell renal cell carcinoma [2]. Therefore, combining PLOD2 inhibition with immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1) may enhance the efficacy of immunotherapy. In ccRCC, a hypoxia-driven immune escape model identified PLOD2 as a dual-functional biomarker for immunotherapy stratification, suggesting that patients with high PLOD2 expression may benefit from combination therapy targeting both hypoxia and immune checkpoints [2].

### 6.6 Zoledronate Therapy in Bruck Syndrome

For patients with BRKS2, there is no targeted therapy that corrects the underlying PLOD2 deficiency. However, bisphosphonates such as zoledronate are used to manage bone fragility. A case report demonstrated significant clinical improvement following intravenous zoledronate therapy in a patient with BRKS2 due to a rare PLOD2 gene variant [3]. Zoledronate inhibits osteoclast-mediated bone resorption, thereby increasing bone mineral density and reducing fracture risk, but it does not address the underlying collagen cross-linking defect.

---

## 7. Bioinformatic Resources & Database Accessions

| Database | Accession/Identifier | URL |
|---|---|---|
| HGNC | HGNC:9082 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:9082 |
| NCBI Gene | 5352 | https://www.ncbi.nlm.nih.gov/gene/5352 |
| Ensembl | ENSG00000152952 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?db=core;g=ENSG00000152952 |
| UniProt | O00469 | https://www.uniprot.org/uniprotkb/O00469/entry |
| RCSB PDB | Multiple entries (e.g., 6ZWV for PLOD1 homolog) | https://www.rcsb.org/ |
| OMIM | 601865 (PLOD2); 609220 (Bruck syndrome 2) | https://www.omim.org/entry/601865 |
| ClinVar | PLOD2 | https://www.ncbi.nlm.nih.gov/clinvar/?term=PLOD2 |
| GTEx | PLOD2 | https://gtexportal.org/home/gene/PLOD2 |
| STRING | PLOD2 (Homo sapiens) | https://string-db.org/network/9606.ENSP00000264498 |
| BioGRID | PLOD2 | https://thebiogrid.org/ |
| Gene Ontology (GO) | GO:0005506 (iron ion binding); GO:0005515 (protein binding); GO:0016702 (oxidoreductase activity); GO:0009791 (post-embryonic development); GO:0030199 (collagen fibril organization) | https://www.ebi.ac.uk/QuickGO/ |
| KEGG | hsa:5352 | https://www.genome.jp/dbget-bin/www_bget?hsa:5352 |
| Reactome | R-HSA-1650814 (collagen biosynthesis and modifying enzymes) | https://reactome.org/content/detail/R-HSA-1650814 |
| Human Protein Atlas | ENSG00000152952 | https://www.proteinatlas.org/ENSG00000152952-PLOD2 |
| COSMIC | PLOD2 | https://cancer.sanger.ac.uk/cosmic/gene/analysis?ln=PLOD2 |
| cBioPortal | PLOD2 | https://www.cbioportal.org/ |

---

## Related Clinical & Scientific Guides

* [UTY Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/uty-gene-structure-function-pathway)
* [ZBTB42 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/zbtb42-gene-structure-function-pathway)
* [TTLL8 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/metabolic-pathways/ttll8-gene-structure-function-pathway)

## References

[1] Bolshakova O, Latypova E, Komissarov A, Slobodina AD, Ryabova EV, Varfolomeeva E, Agranovich O, Batkin SF, Sarantseva S. Cellular and Molecular Effects of the Bruck Syndrome-Associated Mutation in the PLOD2 Gene. Int J Mol Sci. 2024. https://www.semanticscholar.org/paper/f3a3889d33da44058cd736b64a32ab3b36b0c49b

[2] Van Den Langenbergh JV, Bastiaansen-Jenniskens Y, van Osch G, Runhaar J, Bierma-Zeinstra S, Soballe K, Laursen J, Liljensøe A, Kops N, Mechlenburg I, Clockaerts S, Leuven K. PLOD2 gene expression in infrapatellar fat pad is correlated with fat mass in obese patients with end-stage knee osteoarthritis. Osteoarthritis Cartilage Open. 2024. https://www.semanticscholar.org/paper/8fd5c70e011d6470d1baa2fba8c3374b0cf2791c

[3] Patra S,